Image For Activity Cover
Newly Opened Phase 3 Study for Low Grade Serous Ovarian Cancer
Description
Listen in to this recording to learn more about a potential clinical trial for your patients. The RAMP 301 trial is evaluating the novel combination of avutometinib + defactinib versus investigator’s choice of therapy in patients with recurrent low grade serous ovarian cancer.

Recorded on April 15, 2024
Duration approximately 30 minutes

Attended previous IGCS webinars? If you have attended IGCS webinars in the past, you may already have an IGCS account and creating a new account is not required. If unsure of your login information, you may reset your information by selecting "Forgot Password" at login or contact education@igcs.org.

If you have questions or need assistance, contact education@igcs.org.
Faculty Information

Rachel Grisham, MD
Section Head Ovarian Cancer
Director, Gynecologic Medical Oncology
Memorial Sloan Kettering Cancer Center
USA

Susana Banerjee, MBBS, MA, PhD, FRCP
Consultant Medical Oncologist
Research Lead Gynaecology Unit
The Royal Marsden
UK

Supported in part by
Summary
Availability: On-Demand
Cost: FREE
Recommended
Contact education@igcs.org for assistance.
Powered By